MA34158B1 - Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée - Google Patents
Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituéeInfo
- Publication number
- MA34158B1 MA34158B1 MA35308A MA35308A MA34158B1 MA 34158 B1 MA34158 B1 MA 34158B1 MA 35308 A MA35308 A MA 35308A MA 35308 A MA35308 A MA 35308A MA 34158 B1 MA34158 B1 MA 34158B1
- Authority
- MA
- Morocco
- Prior art keywords
- dihydroimidazo
- component
- quinazoline
- combinations
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne : * des combinaisons de : composant A : un ou plusieurs composés de 2,3-dihydroimidazo[1,2-c]quinazoline de formule générale (A1) ou (A2), ou un sel, solvate, hydrate ou stéréoisomère physiologiquement acceptable de celui-ci; composant B : un ou plusieurs composés de N-(2-arylamino)arylsulfonamide de formule générale (B), ou lapatinib, ou paclitaxel, ou un sel, solvate, hydrate ou stéréoisomère physiologiquement acceptable de celui-ci; et, facultativement, composant C : un ou plusieurs autres agents pharmaceutiques; où facultativement certains ou tous les composants sont sous la forme d'une formulation pharmaceutique qui est prête pour utilisation pour être administrés simultanément, conjointement, séparément ou séquentiellement, dépendamment les uns des autres, par voie orale, intraveineuse, topique, locale, par instillation, intrapéritonéale ou nasale; * l'utilisation de telles combinaisons pour la préparation d'un médicament pour le traitement ou la prophylaxie d'un cancer; et * un kit comprenant une telle combinaison.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10160109 | 2010-04-16 | ||
PCT/EP2011/055917 WO2011128407A2 (fr) | 2010-04-16 | 2011-04-14 | Combinaisons contenant une 2,3-dihydroimidazo[1,2-c]quinazoline substituée |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34158B1 true MA34158B1 (fr) | 2013-04-03 |
Family
ID=44144895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35308A MA34158B1 (fr) | 2010-04-16 | 2011-04-14 | Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée |
Country Status (24)
Country | Link |
---|---|
US (1) | US20130184270A1 (fr) |
EP (1) | EP2558126A2 (fr) |
JP (1) | JP5886271B2 (fr) |
KR (1) | KR20130098155A (fr) |
CN (1) | CN102958540B (fr) |
AU (1) | AU2011240003A1 (fr) |
BR (1) | BR112012026480A2 (fr) |
CA (1) | CA2796253A1 (fr) |
CL (1) | CL2012002887A1 (fr) |
CO (1) | CO6620036A2 (fr) |
CR (1) | CR20120524A (fr) |
CU (1) | CU20120150A7 (fr) |
DO (1) | DOP2012000269A (fr) |
EA (1) | EA201201414A8 (fr) |
EC (1) | ECSP12012261A (fr) |
HK (1) | HK1182937A1 (fr) |
IL (1) | IL222356A0 (fr) |
MA (1) | MA34158B1 (fr) |
MX (1) | MX2012012064A (fr) |
PE (1) | PE20130191A1 (fr) |
SG (1) | SG184550A1 (fr) |
TN (1) | TN2012000493A1 (fr) |
WO (1) | WO2011128407A2 (fr) |
ZA (1) | ZA201208616B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2168583A1 (fr) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome |
UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
EP2508525A1 (fr) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés |
JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
WO2014160034A1 (fr) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Modulateurs d'aldéhyde déshydrogénase-1 et leurs procédés d'utilisation |
PE20151780A1 (es) | 2013-04-08 | 2015-12-20 | Bayer Pharma AG | Uso de 2 - 3 dihidroimidazo[ 1,2- c] quinazolinas sustituidas |
WO2015082376A2 (fr) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Utilisation d'inhibiteurs de pi3k |
TN2017000385A1 (en) * | 2015-03-09 | 2019-01-16 | Bayer Healthcare Pharmaceuticals Inc | Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines. |
SG11201707240SA (en) * | 2015-03-09 | 2017-10-30 | Bayer Pharma AG | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
WO2017153220A1 (fr) * | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
CA3068324A1 (fr) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combinaison d'un inhibiteur de pi3k et d'un antagoniste du recepteur des androgenes |
US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
MXPA05001808A (es) | 2002-09-30 | 2005-08-16 | Bayer Pharmaceuticals Corp | Derivados de azol-pirimidina condensados. |
JP4323793B2 (ja) | 2002-12-16 | 2009-09-02 | キヤノン株式会社 | ズームレンズ及びそれを有する光学機器 |
DE102004064002B4 (de) | 2004-08-04 | 2019-05-09 | Continental Automotive Gmbh | System zum Überwachen einer Sensorvorrichtung |
PL1912636T3 (pl) | 2005-07-21 | 2015-02-27 | Ardea Biosciences Inc | N-(aryloamino)sulfonamidowe inhibitory mek |
US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
EA201001639A1 (ru) * | 2008-04-14 | 2011-06-30 | Арди Байосайенсиз, Инк. | Композиции и способы их получения и применения |
EP2168583A1 (fr) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome |
-
2011
- 2011-04-14 MX MX2012012064A patent/MX2012012064A/es unknown
- 2011-04-14 AU AU2011240003A patent/AU2011240003A1/en not_active Abandoned
- 2011-04-14 JP JP2013504278A patent/JP5886271B2/ja not_active Expired - Fee Related
- 2011-04-14 WO PCT/EP2011/055917 patent/WO2011128407A2/fr active Application Filing
- 2011-04-14 PE PE2012002028A patent/PE20130191A1/es not_active Application Discontinuation
- 2011-04-14 US US13/640,994 patent/US20130184270A1/en not_active Abandoned
- 2011-04-14 SG SG2012075511A patent/SG184550A1/en unknown
- 2011-04-14 KR KR1020127029890A patent/KR20130098155A/ko not_active Application Discontinuation
- 2011-04-14 MA MA35308A patent/MA34158B1/fr unknown
- 2011-04-14 BR BR112012026480A patent/BR112012026480A2/pt not_active IP Right Cessation
- 2011-04-14 CA CA2796253A patent/CA2796253A1/fr not_active Abandoned
- 2011-04-14 EA EA201201414A patent/EA201201414A8/ru unknown
- 2011-04-14 CN CN201180029827.XA patent/CN102958540B/zh not_active Expired - Fee Related
- 2011-04-14 EP EP11714553A patent/EP2558126A2/fr not_active Withdrawn
-
2012
- 2012-10-11 IL IL222356A patent/IL222356A0/en unknown
- 2012-10-12 TN TNP2012000493A patent/TN2012000493A1/en unknown
- 2012-10-15 EC ECSP12012261 patent/ECSP12012261A/es unknown
- 2012-10-16 CL CL2012002887A patent/CL2012002887A1/es unknown
- 2012-10-16 CR CR20120524A patent/CR20120524A/es unknown
- 2012-10-16 DO DO2012000269A patent/DOP2012000269A/es unknown
- 2012-10-16 CU CU2012000150A patent/CU20120150A7/es unknown
- 2012-10-16 CO CO12182241A patent/CO6620036A2/es not_active Application Discontinuation
- 2012-11-15 ZA ZA2012/08616A patent/ZA201208616B/en unknown
-
2013
- 2013-09-03 HK HK13110265.2A patent/HK1182937A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20130098155A (ko) | 2013-09-04 |
US20130184270A1 (en) | 2013-07-18 |
CU20120150A7 (es) | 2013-02-26 |
MX2012012064A (es) | 2012-12-17 |
JP5886271B2 (ja) | 2016-03-16 |
CA2796253A1 (fr) | 2011-10-20 |
SG184550A1 (en) | 2012-11-29 |
WO2011128407A9 (fr) | 2011-12-22 |
CN102958540B (zh) | 2015-09-02 |
HK1182937A1 (en) | 2013-12-13 |
CO6620036A2 (es) | 2013-02-15 |
WO2011128407A3 (fr) | 2012-02-23 |
CR20120524A (es) | 2013-01-09 |
ECSP12012261A (es) | 2012-11-30 |
AU2011240003A1 (en) | 2012-11-08 |
EA201201414A8 (ru) | 2013-12-30 |
JP2013525293A (ja) | 2013-06-20 |
CN102958540A (zh) | 2013-03-06 |
TN2012000493A1 (en) | 2014-04-01 |
ZA201208616B (en) | 2015-08-26 |
DOP2012000269A (es) | 2012-12-15 |
PE20130191A1 (es) | 2013-02-21 |
EA201201414A1 (ru) | 2013-04-30 |
EP2558126A2 (fr) | 2013-02-20 |
WO2011128407A2 (fr) | 2011-10-20 |
CL2012002887A1 (es) | 2013-01-18 |
BR112012026480A2 (pt) | 2016-08-16 |
IL222356A0 (en) | 2012-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34158B1 (fr) | Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée | |
MA34553B1 (fr) | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué | |
ES2928408T3 (es) | Métodos para el tratamiento de enfermedades fibróticas | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA34083B1 (fr) | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
JP6456383B2 (ja) | イソチオシアネート系化合物と抗癌薬の併用 | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
EA200601724A1 (ru) | Новые композиции для местной доставки | |
BRPI0511967B8 (pt) | derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende | |
RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
JP2002520273A (ja) | 抗うつ効果を有する治療薬 | |
TW200633978A (en) | 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists | |
MA44206B1 (fr) | Comprimé orodispersible comprenant estetrol | |
MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
US8906951B1 (en) | Use of NK-1 receptor antagonists in pruritus | |
MA45043A (fr) | Composés pour stimuler la croissance des cheveux et/ou inhiber ou retarder la chute des cheveux chez l'homme, et compositions pour de telles utilisations | |
MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
EA202190115A1 (ru) | Пленочные составы, содержащие дексмедетомидин, и способы их получения | |
JP2018517759A5 (fr) | ||
BRPI0716214A2 (pt) | Composições farmacêuticas para o tratamento de infecções fúngicas. |